Section Arrow
Quote
RARE.NASDAQ
- Ultragenyx Pharmaceutical
Quotes are at least 15-min delayed:2024/12/23 22:27 EST
Last
 43.87
-0.35 (-0.79%)
Day High 
44.2 
Prev. Close
44.22 
1-M High
50 
Volume 
697.46K 
Bid
42.7
Ask
43.88
Day Low
43 
Open
44.02 
1-M Low
41.45 
Market Cap 
4.08B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 46.09 
20-SMA 46.83 
50-SMA 49.67 
52-W High 60.37 
52-W Low 37.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.35/-4.81
Enterprise Value
4.11B
Balance Sheet
Book Value Per Share
3.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
434.25M
Operating Revenue Per Share
4.44
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed：2024/12/23 22:27 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.